Medimmune stops arthritis and psoriasis trials

By Staff Writers
Tuesday, 31 August, 2004

Maryland-based MedImmune has halted the clinical trials of its Vitaxin drug for rheumatoid arthritis and psoriasis, blaming a lack of benefits seen with the experimental treatment.

The drug maker said no safety issues came up during the trial. It will continue to study the compound to treat cancer.

'Low-risk' antibiotic linked to rise of dangerous superbug

A new study has challenged the long-held belief that rifaximin — commonly prescribed to...

Robotic hand helps cultivate baby corals for reef restoration

The soft robotic hand could revolutionise the delicate, labour-intensive process of cultivating...

Stem cell experiments conducted in space

Scientists are one step closer to manufacturing stem cells in space — which could speed up...

Content from other channels on our network

Three states announce BESS projects in a week

Emerson offers solution to reduce energy costs and emissions

CSIRO solar venture nets record seed funding

Rockwell Automation and Microsoft expand cloud and AI partnership

Major US defence company sets up in SA

Making Australian canola oil more sustainable with solar power

Fonterra charts progress against its 'Climate Roadmap'

Who will pay for emission reductions in the milk sector?

How to manage safety risks in the low-moisture food sector?

Pure Dairy appoints new CCO

Rising healthcare facility demands pave way for innovation

Designs unveiled for the new Melton Hospital

AIA Australia launches virtual mental health service

Depressive disorders: 70% of Australians not getting adequate treatment

High blood pressure costs Australia $1.2bn a year